These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

263 related items for PubMed ID: 16797489

  • 1. KR-62980: a novel peroxisome proliferator-activated receptor gamma agonist with weak adipogenic effects.
    Kim KR, Lee JH, Kim SJ, Rhee SD, Jung WH, Yang SD, Kim SS, Ahn JH, Cheon HG.
    Biochem Pharmacol; 2006 Aug 14; 72(4):446-54. PubMed ID: 16797489
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. A selective peroxisome proliferator-activated receptor gamma modulator with distinct fat cell regulation properties.
    Fujimura T, Kimura C, Oe T, Takata Y, Sakuma H, Aramori I, Mutoh S.
    J Pharmacol Exp Ther; 2006 Aug 14; 318(2):863-71. PubMed ID: 16682454
    [Abstract] [Full Text] [Related]

  • 4. A novel selective peroxisome proliferator-activator receptor-gamma modulator-SPPARgammaM5 improves insulin sensitivity with diminished adverse cardiovascular effects.
    Chang CH, McNamara LA, Wu MS, Muise ES, Tan Y, Wood HB, Meinke PT, Thompson JR, Doebber TW, Berger JP, McCann ME.
    Eur J Pharmacol; 2008 Apr 14; 584(1):192-201. PubMed ID: 18346728
    [Abstract] [Full Text] [Related]

  • 5. 18F9 (4-(3,6-bis (ethoxycarbonyl)-4,5,6,7-tetrahydrothieno (2,3-c) pyridin-2-ylamino)-4-oxobutanoic acid) enhances insulin-mediated glucose uptake in vitro and exhibits antidiabetic activity in vivo in db/db mice.
    Anandharajan R, Sayyed SG, Doshi LS, Dixit P, Chandak PG, Dixit AV, Brahma MK, Deshmukh NJ, Gupte R, Damre A, Suthar J, Padigaru M, Sharma SD, Nemmani KV.
    Metabolism; 2009 Oct 14; 58(10):1503-16. PubMed ID: 19608207
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Bixin regulates mRNA expression involved in adipogenesis and enhances insulin sensitivity in 3T3-L1 adipocytes through PPARgamma activation.
    Takahashi N, Goto T, Taimatsu A, Egawa K, Katoh S, Kusudo T, Sakamoto T, Ohyane C, Lee JY, Kim YI, Uemura T, Hirai S, Kawada T.
    Biochem Biophys Res Commun; 2009 Dec 25; 390(4):1372-6. PubMed ID: 19891958
    [Abstract] [Full Text] [Related]

  • 9. Anti-diabetic and anti-adipogenic effects of a novel selective 11β-hydroxysteroid dehydrogenase type 1 inhibitor, 2-(3-benzoyl)-4-hydroxy-1,1-dioxo-2H-1,2-benzothiazine-2-yl-1-phenylethanone (KR-66344).
    Park JS, Rhee SD, Kang NS, Jung WH, Kim HY, Kim JH, Kang SK, Cheon HG, Ahn JH, Kim KY.
    Biochem Pharmacol; 2011 Apr 15; 81(8):1028-35. PubMed ID: 21315688
    [Abstract] [Full Text] [Related]

  • 10. NS-1: a novel partial peroxisome proliferator-activated receptor γ agonist to improve insulin sensitivity and metabolic profile.
    Chaudhary S, Dube A, Kothari V, Sachan N, Upasani CD.
    Eur J Pharmacol; 2012 Jun 05; 684(1-3):154-60. PubMed ID: 22484334
    [Abstract] [Full Text] [Related]

  • 11. PAR-5359, a well-balanced PPARalpha/gamma dual agonist, exhibits equivalent antidiabetic and hypolipidemic activities in vitro and in vivo.
    Kim MK, Chae YN, Son MH, Kim SH, Kim JK, Moon HS, Park CS, Bae MH, Kim E, Han T, Choi HH, Shin YA, Ahn BN, Lee CH, Lim JI, Shin CY.
    Eur J Pharmacol; 2008 Oct 24; 595(1-3):119-25. PubMed ID: 18727927
    [Abstract] [Full Text] [Related]

  • 12. Antagonism of peroxisome proliferator-activated receptor gamma prevents high-fat diet-induced obesity in vivo.
    Nakano R, Kurosaki E, Yoshida S, Yokono M, Shimaya A, Maruyama T, Shibasaki M.
    Biochem Pharmacol; 2006 Jun 28; 72(1):42-52. PubMed ID: 16696951
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Kaempferol and quercetin isolated from Euonymus alatus improve glucose uptake of 3T3-L1 cells without adipogenesis activity.
    Fang XK, Gao J, Zhu DN.
    Life Sci; 2008 Mar 12; 82(11-12):615-22. PubMed ID: 18262572
    [Abstract] [Full Text] [Related]

  • 15. Molecular determinants of FGF-21 activity-synergy and cross-talk with PPARgamma signaling.
    Moyers JS, Shiyanova TL, Mehrbod F, Dunbar JD, Noblitt TW, Otto KA, Reifel-Miller A, Kharitonenkov A.
    J Cell Physiol; 2007 Jan 12; 210(1):1-6. PubMed ID: 17063460
    [Abstract] [Full Text] [Related]

  • 16. Hypoglycemic action of thiazolidinediones/peroxisome proliferator-activated receptor gamma by inhibition of the c-Jun NH2-terminal kinase pathway.
    Díaz-Delfín J, Morales M, Caelles C.
    Diabetes; 2007 Jul 12; 56(7):1865-71. PubMed ID: 17416798
    [Abstract] [Full Text] [Related]

  • 17. The DLK gene is a transcriptional target of PPARγ.
    Couture JP, Blouin R.
    Biochem J; 2011 Aug 15; 438(1):93-101. PubMed ID: 21585338
    [Abstract] [Full Text] [Related]

  • 18. Dissociation of antihyperglycaemic and adverse effects of partial perioxisome proliferator-activated receptor (PPAR-gamma) agonist balaglitazone.
    Larsen PJ, Lykkegaard K, Larsen LK, Fleckner J, Sauerberg P, Wassermann K, Wulff EM.
    Eur J Pharmacol; 2008 Oct 31; 596(1-3):173-9. PubMed ID: 18761337
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Augmentation of PPARgamma-TAZ interaction contributes to the anti-adipogenic activity of KR62980.
    Jung H, Lee MS, Jang EJ, Ahn JH, Kang NS, Yoo SE, Bae MA, Hong JH, Hwang ES.
    Biochem Pharmacol; 2009 Nov 15; 78(10):1323-9. PubMed ID: 19591806
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.